Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab as salvage therapy in patients with neo wild-type RAS/RAF metastatic colorectal cancer
2019-002115-26Phase 2Terminated
- Sponsor
- Institut Hospitalier Franco-Britannique
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cetuximab in colorectal cancer (CRC) (2 arms), sponsored by Institut Hospitalier Franco-Britannique. Primary endpoint: Objective response rate. Started Sep 2019; status: terminated.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2019-002115-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002115-26.